Le SIDA en Afrique subsaharienne (serveur d'exploration) - Exploration (Accueil)

Index « Mesh.i » - entrée « Cost-Benefit Analysis »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Cost of Illness < Cost-Benefit Analysis < Costs and Cost Analysis  Facettes :

List of bibliographic references indexed by Cost-Benefit Analysis

Number of relevant bibliographic references: 29.
[0-20] [0 - 20][0 - 29][20-28][20-40]
Ident.Authors (with country if any)Title
000148 (2017) Gavin George [Afrique du Sud] ; Michael Strauss [Afrique du Sud] ; Elias Asfaw [Afrique du Sud]The cost of demand creation activities and voluntary medical male circumcision targeting school-going adolescents in KwaZulu-Natal, South Africa.
000181 (2017) Omar Galárraga [États-Unis] ; Burke Gao [États-Unis] ; Benson N. Gakinya [Kenya] ; Debra A. Klein [États-Unis] ; Richard G. Wamai [États-Unis] ; John E. Sidle [États-Unis] ; Rebecca K. Papas [États-Unis]Task-shifting alcohol interventions for HIV+ persons in Kenya: a cost-benefit analysis.
000865 (2017) Naseem Cassim [Afrique du Sud] ; Kathryn Schnippel [Afrique du Sud] ; Lindi Marie Coetzee [Afrique du Sud] ; Deborah Kim Glencross [Afrique du Sud]Establishing a cost-per-result of laboratory-based, reflex Cryptococcal antigenaemia screening (CrAg) in HIV+ patients with CD4 counts less than 100 cells/μl using a Lateral Flow Assay (LFA) at a typical busy CD4 laboratory in South Africa.
000905 (2017) Elias Asfaw Zegeye [Afrique du Sud] ; Josue Mbonigaba [Afrique du Sud] ; Sylvia Blanche Kaye [Afrique du Sud] ; Thomas Wilkinson [Afrique du Sud]Economic Evaluation in Ethiopian Healthcare Sector Decision Making: Perception, Practice and Barriers.
001989 (2014) Michael D. April [États-Unis] ; Robin Wood ; Bethany K. Berkowitz ; A David Paltiel ; Xavier Anglaret ; Elena Losina ; Kenneth A. Freedberg ; Rochelle P. WalenskyThe survival benefits of antiretroviral therapy in South Africa.
001995 (2014) John Fieno [Afrique du Sud] ; Suzanne Leclerc-MadlalaThe promise and limitations of cash transfer programs for HIV prevention.
002207 (2013) L. Renner [Ghana] ; F A Nkansah ; A N O. DodooThe role of generic medicines and biosimilars in oncology in low-income countries.
002217 (2013) Karen Schneider [Australie] ; Chidi Nwizu ; Richard Kaplan ; Jonathan Anderson ; David P. Wilson ; Sean Emery ; David A. Cooper ; Mark A. BoydThe potential cost and benefits of raltegravir in simplified second-line therapy among HIV infected patients in Nigeria and South Africa.
002220 (2013) Ide Cremin [Royaume-Uni] ; Ramzi Alsallaq ; Mark Dybul ; Peter Piot ; Geoffrey Garnett ; Timothy B. HallettThe new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis.
002238 (2013) Noreen Dadirai Mdege [Royaume-Uni] ; Stanley Chindove ; Shehzad AliThe effectiveness and cost implications of task-shifting in the delivery of antiretroviral therapy to HIV-infected patients: a systematic review.
002251 (2013) Julie H. Levison [États-Unis] ; Robin Wood ; Callie A. Scott ; Andrea L. Ciaranello ; Neil A. Martinson ; Corina Rusu ; Elena Losina ; Kenneth A. Freedberg ; Rochelle P. WalenskyThe clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa.
002645 (2013) Thu-Ha Dinh [Afrique du Sud] ; Mary L. Kamb ; Veerle Msimang ; Muptal Likibi ; Thabo Molebatsi ; Thurma Goldman ; David A. LewisIntegration of preventing mother-to-child transmission of HIV and syphilis testing and treatment in antenatal care services in the Northern Cape and Gauteng provinces, South Africa.
002673 (2013) Sebastian Kevany [États-Unis] ; Solomon R. Benatar ; Theodore FleischerImproving resource allocation decisions for health and HIV programmes in South Africa: Bioethical, cost-effectiveness and health diplomacy considerations.
002739 (2013) Jeffrey W. Eaton [Royaume-Uni] ; Nicolas A. Menzies [États-Unis] ; John Stover [États-Unis] ; Valentina Cambiano [Royaume-Uni] ; Leonid Chindelevitch [États-Unis] ; Anne Cori [Royaume-Uni] ; Jan A C. Hontelez [Pays-Bas] ; Salal Humair [États-Unis] ; Cliff C. Kerr [Australie] ; Daniel J. Klein [États-Unis] ; Sharmistha Mishra [Canada] ; Kate M. Mitchell [Royaume-Uni] ; Brooke E. Nichols [Pays-Bas] ; Peter Vickerman [Royaume-Uni] ; Roel Bakker [Pays-Bas] ; Till B Rnighausen [États-Unis] ; Anna Bershteyn [États-Unis] ; David E. Bloom [États-Unis] ; Marie-Claude Boily [Royaume-Uni] ; Stewart T. Chang [États-Unis] ; Ted Cohen [États-Unis] ; Peter J. Dodd [Royaume-Uni] ; Christophe Fraser [Royaume-Uni] ; Chaitra Gopalappa [États-Unis] ; Jens Lundgren [Danemark] ; Natasha K. Martin [Royaume-Uni] ; Evelinn Mikkelsen [Pays-Bas] ; Elisa Mountain [Royaume-Uni] ; Quang D. Pham [Australie] ; Michael Pickles [Royaume-Uni] ; Andrew Phillips [Royaume-Uni] ; Lucy Platt [Royaume-Uni] ; Carel Pretorius [États-Unis] ; Holly J. Prudden [Royaume-Uni] ; Joshua A. Salomon [États-Unis] ; David A M C. Van De Vijver [Pays-Bas] ; Sake J. De Vlas [Pays-Bas] ; Bradley G. Wagner [États-Unis] ; Richard G. White [Royaume-Uni] ; David P. Wilson [Australie] ; Lei Zhang [Australie] ; John Blandford [États-Unis] ; Gesine Meyer-Rath [Afrique du Sud] ; Michelle Remme [Royaume-Uni] ; Paul Revill [Royaume-Uni] ; Nalinee Sangrujee [États-Unis] ; Fern Terris-Prestholt [Royaume-Uni] ; Meg Doherty [Suisse] ; Nathan Shaffer [Suisse] ; Philippa J. Easterbrook [Suisse] ; Gottfried Hirnschall [Suisse] ; Timothy B. Hallett [Royaume-Uni]Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.
002867 (2013) Avinash K. Shetty [États-Unis]Epidemiology of HIV infection in women and children: a global perspective.
002968 (2013) Janne Estill [Suisse] ; Matthias Egger ; Nello Blaser ; Luisa Salazar Vizcaya ; Daniela Garone ; Robin Wood ; Jennifer Campbell ; Timothy B. Hallett ; Olivia KeiserCost-effectiveness of point-of-care viral load monitoring of antiretroviral therapy in resource-limited settings: mathematical modelling study.
002969 (2013) Garry R. Barton [Royaume-Uni] ; Lara Fairall ; Max O. Bachmann ; Kerry Uebel ; Venessa Timmerman ; Carl Lombard ; Merrick ZwarensteinCost-effectiveness of nurse-led versus doctor-led antiretroviral treatment in South Africa: pragmatic cluster randomised trial.
002972 (2013) Joseph N. Jarvis [Royaume-Uni] ; Thomas S. Harrison ; Stephen D. Lawn ; Graeme Meintjes ; Robin Wood ; Susan ClearyCost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa.
002973 (2013) Gesine Meyer-Rath [États-Unis] ; Alana Brennan ; Lawrence Long ; Buyiswa Ndibongo ; Karl Technau ; Harry Moultrie ; Lee Fairlie ; Ashraf Coovadia ; Sydney RosenCost and outcomes of paediatric antiretroviral treatment in South Africa.
002A09 (2013) Rochelle P. Walensky [États-Unis]Combination HIV prevention: the value and interpretation of mathematical models.
002B07 (2013) Kazeem O. Okosun [Afrique du Sud] ; Oluwole D. Makinde ; Isaac TakaidzaAnalysis of recruitment and industrial human resources management for optimal productivity in the presence of the HIV/AIDS epidemic.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Mesh.i -k "Cost-Benefit Analysis" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Mesh.i  \
                -Sk "Cost-Benefit Analysis" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    SidaSubSaharaV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    Mesh.i
   |clé=    Cost-Benefit Analysis
}}

Wicri

This area was generated with Dilib version V0.6.32.
Data generation: Mon Nov 13 19:31:10 2017. Site generation: Wed Mar 6 19:14:32 2024